EASY TECHNOLOGIES INC.

PRESS RELEASE

EASY TECHNOLOGIES INC. AND SHANGHAI BIOTECHNOLOGY DEVICES LIMITED ANNOUNCE PROPOSED TRANSACTION

Vancouver, BC: April 27, 2021 – Easy Technologies Inc. (**"Easy"** or the **"Company"**) and Shanghai Biotechnology Devices Limited (**"Virax Biolabs"**) are pleased to announce that they have entered into a binding letter of intent to complete a business combination (the **"Transaction"**). The letter of intent was negotiated at arm's length and is effective as of April 22, 2021.

INFORMATION CONCERNING THE PROPOSED TRANSACTION

Easy and Virax Biolabs are proposing to enter into a business combination by way of an amalgamation, share exchange, arrangement or other similar form of Transaction which will result in Virax Biolabs combining its corporate existence with that of Easy. The parties agree that the final structure of the business combination is subject to receipt of tax, corporate and securities law advice for both Easy and Virax Biolabs.

The authorized share capital of Easy currently consists of an unlimited number of common shares (the "**Easy Shares**") without par value, of which a total of 10,111,332 Easy Shares are issued and outstanding and no other Easy Shares are reserved for issuance.

Virax Biolabs currently has 80,000,020 common shares issued and outstanding (the "**Virax Shares**"), and will have no more than 100,000,000 Virax Shares outstanding on a fully diluted basis for the purposes of this Transaction, other than securities issued in connection with the Bridge Financing and Concurrent Financing (each as defined herein).

Prior to or concurrent with the Transaction, Virax Biolabs may undertake a bridge financing (the "**Bridge Financing**") on a non-brokered private placement basis by issuing convertible debentures for aggregate gross proceeds of up to $1,000,000, with each convertible debenture automatically converting into Virax Shares immediately prior to completing the Transaction at a conversion price equal to a 20% discount to price of a Subscription Receipt (as defined herein).

Prior to or concurrent with the Transaction, Virax Biolabs will complete a brokered private placement (the "**Concurrent Financing**") of up to $5,000,000 by way of subscription receipts (the "**Subscription Receipts**"). The Subscription Receipts will automatically be converted into units of Virax Biolabs, with each unit being comprised of one Virax Shares and one-half of one Virax Share purchase warrant, and which securities shall be subsequently exchanged for equivalent securities of the resulting issuer upon completion of the Transaction.

SHAREHOLDERS' SPECIAL MEETING

In connection with the business combination, to the extent necessary, Easy will call a special meeting of its shareholders in order to: (i) approve the Transaction; (ii) approve the change of its name to "Virax Biolabs", or such other name Virax Biolabs may determine; and (iii) approve such other things as is necessary to complete the Transaction.

Further, Virax Biolabs will call a special meeting of its shareholders in order to approve any such things as is necessary to complete the Transaction.

BOARD OF DIRECTORS AND OFFICERS

Upon closing of the contemplated Transaction, the current board of directors of Easy shall resign. Following completion of the contemplated Transaction, the officers of Virax Biolabs shall be the proposed and unchallenged nominees of Easy.

ON BEHALF OF THE BOARD

Michel Lebeuf Jr.
Interim President

Further information regarding the Company can be found on SEDAR at www.SEDAR.com, or by contacting the Company directly at (778) 370-1372.

This news release may contain forward–looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Forward-looking statements in this press release may include, without limitation, the anticipated completion of the Transaction, the Concurrent Financing and the Bridge Financing. Actual results may differ materially from those currently anticipated in such statements. Particular risks applicable to this press release include risks associated with planned production, including the ability of the company to achieve its targeted production outline due to regulatory, technical or economic factors. In addition, there are risks associated with estimates of resources, and there is no guarantee that a resource will have demonstrated economic viability as necessary to be classified as a reserve. There is no guarantee that additional exploration work will result in significant increases to resource estimates

No Canadian Securities Exchange nor any Regulation Services Provider (as that term is defined in policies of the any Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.